Reducing the Risk of Type 2 Diabetes in Nonselected Outpatients with Schizophrenia: A 30-Month Program

Journal of Psychiatric Practice

Volumn 24, Issue 1, 2018, Pages 21-31

  Hjorth, Peter ^a   Espensen, Caroline H ^b   Madsen, Nikolaj J ^c   Viuff, Anne G ^d   Munk JØrgensen, Povl ^e  

^a Psychiatric Hospital   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d Regional Psychiatric Services West   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

intervention; physical health; prevention; s chizophrenia; type 2 diabetes

Indexed keywords

ALCOHOL; CANNABIS; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY FAT; BODY FAT DISTRIBUTION; BODY WEIGHT; CARDIOMETABOLIC RISK; CLINICAL EVALUATION; CLINICAL PRACTICE; COFFEE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; EVIDENCE BASED PRACTICE; FAST FOOD; FEMALE; FOLLOW UP; HEALTH PROMOTION; HUMAN; INFORMATION PROCESSING; LIFESTYLE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MOTIVATIONAL INTERVIEWING; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; OUTPATIENT; PHYSICAL ACTIVITY; RUNNING; SCHIZOPHRENIA; SLEEP; SMOKING CESSATION; SOCIAL CARE; SOFT DRINK; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VISCERAL ADIPOSITY INDEX; WAIST CIRCUMFERENCE; WALKING; ADOLESCENT; COMORBIDITY; DIET THERAPY; KINESIOTHERAPY; MIDDLE AGED; PROCEDURES; PROGRAM DEVELOPMENT; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DIET THERAPY; EXERCISE THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTIVATIONAL INTERVIEWING; PROGRAM DEVELOPMENT; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85045433496     PISSN: 15274160     EISSN: 15381145     Source Type: Journal    
DOI: 10.1097/PRA.0000000000000278     Document Type: Article

References (46)

1. Holt RI. Diagnosis, epidemiology and pathogenesis of diabetes mellitus: an update for psychiatrists. Br J Psychiatry Suppl. 2004;47:S55-S63.
2. De Hert M, Vancampfort D, Correll CU, et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry. 2011;199:99-105.
3. Tuso P. Prediabetes and lifestyle modification: time to prevent a preventable disease. Perm J. 2014;18:88-93.
4. Manu P, Correll CU, van Winkel R, et al. Prediabetes in patients treated with antipsychotic drugs. J Clin Psychiatry. 2012;73:460-466.
5. Steylen PM, van der Heijden FM, Hoogendijk WJ, et al. Glycosylated hemoglobin as a screening test for hyperglycemia in antipsychotic-treated patients: a follow-up study. Diabetes Metab Syndr Obes. 2015;8:57-63.
6. Petersen JL, McGuire DK. Impaired glucose tolerance and impaired fasting glucose-a review of diagnosis, clinical implications and management. Diab Vasc Dis Res. 2005;2:9-15.
7. Tabak AG, Herder C, Rathmann W, et al. Prediabetes: a high-risk state for diabetes development. Lancet. 2012; 379:2279-2290.
8. Aguiar EJ, Morgan PJ, Collins CE, et al. Efficacy of interventions that include diet, aerobic and resistance training components for type 2 diabetes prevention: a systematic review with meta-analysis. Int J Behav Nutr Phys Act. 2014;11:2.
9. Schellenberg ES, Dryden DM, Vandermeer B, et al. Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:543-551.
10. Manu P, Correll CU, Wampers M, et al. Prediabetic increase in hemoglobin A1c compared with impaired fasting glucose in patients receiving antipsychotic drugs. Eur Neuropsychopharmacol. 2013;23:205-211.
11. Hinds A, Coulter L, Hudson J, et al. Screening for diabetes in patients receiving second-generation atypical antipsychotics. Am J Health Syst Pharm. 2015;72: S70-S73.
12. Arnoldy R, Curtis J, Samaras K. The effects of antipsychotic switching on diabetes in chronic schizophrenia. Diabet Med. 2014;31:e16-e19.
13. Allison DB, Mentore JL, Heo M, et al. Antipsychoticinduced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.
14. Daumit GL, Goff DC, Meyer JM, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res. 2008;105:175-187.
15. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007; 64:1123-1131.
16. Parsons B, Allison DB, Loebel A, et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res. 2009;110:103-110.
17. Vanina Y, Podolskaya A, Sedky K, et al. Body weight changes associated with psychopharmacology. Psychiatr Serv. 2002;53:842-847.
18. Amato MC, Giordano C, Pitrone M, et al. Cut-off points of the Visceral Adiposity Index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids Health Dis. 2011;10:183.
19. Chen C, Xu Y, Guo ZR, et al. The application of visceral adiposity index in identifying type 2 diabetes risks based on a prospective cohort in China. Lipids Health Dis. 2014;13:108.
20. Galletly C, Castle D, Dark F, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50:410-472.
21. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007;68 (suppl 4): 8-13.
22. Voogdt-Pruis HR, Van Ree JW, Gorgels AP, et al. Adherence to a guideline on cardiovascular prevention: a comparison between general practitioners and practice nurses. Int J Nurs Stud. 2011;48:798-807.
23. Munk-Jørgensen P, Blanner Kristiansen C, Uwawke R, et al. The gap between available knowledge and its use in clinical psychiatry. Acta Psychiatr Scand. 2015;132: 441-450.
24. Blanner Kristiansen C, Juel A, Vinther Hansen M, et al. Promoting physical health in severe mental illness: patient and staff perspective. Acta Psychiatr Scand. 2015;132:470-478.
25. Medici CR, Vestergaard CH, Hjorth P, et al. Quality of life and clinical characteristics in a nonselected sample of patients with schizophrenia. Int J Soc Psychiatry. 2016;62: 12-20.
26. Hansen MV, Hjorth P, Kristiansen CB, et al. Reducing cardiovascular risk factors in non-selected outpatients with schizophrenia. Int J Soc Psychiatry. 2016;62: 369-376.
27. Hjorth P, Davidsen AS, Kilian R, et al. Improving the physical health of long-term psychiatric inpatients. Aust N Z J Psychiatry. 2014;48:861-870.
28. Pendlebury J, Bushe CJ, Wildgust HJ, et al. Long-term maintenance of weight loss in patients with severe mental illness through a behavioural treatment programme in the UK. Acta Psychiatr Scand. 2007;115: 286-294.
29. Janssen I, Heymsfield SB, Allison DB, et al. Body mass index and waist circumference independently contribute to the prediction of nonabdominal, abdominal subcutaneous, and visceral fat. Am J Clin Nutr. 2002;75: 683-688.
30. Bigaard J, Tjonneland A, Thomsen BL, et al. Waist circumference, BMI, smoking, and mortality in middleaged men and women. Obes Res. 2003;11:895-903.
31. Poulin MJ, Chaput JP, Simard V, et al. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. Aust N Z J Psychiatry. 2007;41:980-989.
32. Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Aust N Z J Psychiatry. 2005;39:479-486.
33. Wang J, Thornton JC, Bari S, et al. Comparisons of waist circumferences measured at 4 sites. Am J Clin Nutr. 2003;77:379-384.
34. World Health Organization (WHO). International Statistical Classification of Diseases and Related Health Problems, Tenth Edition (ICD-10). Geneva, Switzerland: WHO; 1994.
35. Weiser P, Becker T, Losert C, et al. European network for promoting the physical health of residents in psychiatric and social care facilities (HELPS): background, aims and methods. BMC Public Health. 2009;9:315.
36. Hjorth P, Davidsen AS, Kilian R, et al. A systematic review of controlled interventions to reduce overweight and obesity in people with schizophrenia. Acta Psychiatr Scand. 2014;130:279-289.
37. Hjorth P, Kilian R, Sorensen HO, et al. Reducing psychotropic pharmacotherapy in patients with severe mental illness: a cluster-randomized controlled intervention study. Ther Adv Psychopharmacol. 2015;5: 67-75.
38. Miller WR, Rollnick S. Motivational Interviewing: Preparing People for Change, 2nd ed. New York: Guildford Press; 2002.
39. Rollnick S, Miller W, Burker C. Motivational Interviewing in Health Care: Helping Patients Change Behavior. New York: Guilford Press; 2008.
40. Rubak S, Sandbaek A, Lauritzen T, et al. Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract. 2005;55:305-312.
41. Correll CU, Robinson DG, Schooler NR, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISEETP study. JAMA Psychiatry. 2014;71:1350-1363.
42. Battaglia G, Alesi M, Inguglia M, et al. Soccer practice as an add-on treatment in the management of individuals with a diagnosis of schizophrenia. Neuropsychiatr Dis Treat. 2013;9:595-603.
43. Speyer H, Christian Brix Nørgaard H, Birk M, et al. The CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesity. World Psychiatry. 2016;15:155-165.
44. Amato MC, Giordano C, Galia M, et al. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33:920-922.
45. Androulakis II, Kandaraki E, Christakou C, et al. Visceral Adiposity Index (VAI) is related to the severity of anovulation and other clinical features in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2014;81:426-431.
46. Goldani H, Adami FS, Antunes MT, et al. Applicability of the Visceral Adiposity Index (VAI) in the prediction of the components of the metabolic syndrome in elderly. Nutr Hosp. 2015;32:1609-1615.